# What does recent research say about shoulder soreness? *Recent Research — Shoulder Regeneration Peoria Blood-Based Care* > Recent shoulder regeneration Peoria research asks whether care made from blood can ease soreness or improve use of the arm. Can a newer treatment rebuild a sore shoulder? Research hasn't shown a worn tendon growing back after a blood-based procedure. Some people say the ache falls or the arm moves more easily for a time. The result depends on the shoulder problem and the care that was tested. Feeling better doesn't prove that the tendon repaired itself. ## Which research result matters to a sore shoulder? Shoulder research gives a closer answer than a study of knees. The reason for care must match as well. A blood product used during surgery doesn't answer what happens when that product is placed in your shoulder without surgery. Researchers may measure soreness, daily arm use or changes on a scan. A drop in soreness isn't proof that a tendon healed. An unchanged scan doesn't erase relief that you can feel, either. The useful result is one that matches your shoulder problem and daily needs. ## What did the PRP for shoulder pain study find? PRP means platelet-rich plasma, the part kept after spinning blood to raise its platelet level. Clinics may prepare that portion with different platelet levels or amounts of white blood cells. Early results were much like cortisone for soreness in the shoulder tendons. At six months, people given PRP had better arm-use scores and eight-tenths of a point less soreness on the study's pain scale. Researchers called the difference modest, meaning it was small even though PRP scored better. The study found no proof that a tendon grew back. PRP might ease symptoms for a time; it hasn't been shown to rebuild the tendon. ## How can the research help with a decision? Begin with the cause of your soreness. Care studied for an aching tendon may not fit severe joint wear or a frozen shoulder. A sudden tendon tear with weakness needs an exam without much delay. Choose what you want back. That might be sound sleep or an easy reach to a shelf. Then ask how the proposed care compares with exercise, medicine or waiting. A regenerative treatment uses blood or another body tissue, but the name doesn't prove repair. If you don't get a clear answer about likely relief, wait before paying. QC Kinetix medical providers, meaning the team that examines your arm, discuss concentrated PRP and other non-surgical options at Peoria visits. ## Sources 1. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nature medicine*, 2023. DOI: 10.1038/s41591-023-02632-w. 2. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit. Awad G, et al. — [Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/41863718/). *Clinical rheumatology*, 2026. DOI: 10.1007/s10067-026-08042-w. 3. The strongest recent POSITIVE signal: a meta-analysis of 10 RCTs (818 patients, KL I-III) found intra-articular MSC injection beat hyaluronic acid at 12 months on WOMAC total (MD -10.22), VAS (MD -1.31) and on the MRI Whole-Organ Magnetic Resonance Imaging Score (MD -26.01), all reaching the minimal clinically important difference, with no significant difference in adverse events. Recorded here at full weight: this result and the negative RESTORE and Mautner trials are both in the literature, and an honest page reports both. Jin WS, et al. — [Mesenchymal Stem Cells Injection Is More Effective Than Hyaluronic Acid Injection in the Treatment of Knee Osteoarthritis With Similar Safety: A Systematic Review and Meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/39154667/). *Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association*, 2025. DOI: 10.1016/j.arthro.2024.07.027. 4. A network meta-analysis comparing leukocyte-RICH PRP, leukocyte-POOR PRP and hyaluronic acid for knee OA - one of several recent attempts to explain the field's inconsistency by preparation type rather than by whether the therapy works. Formulation heterogeneity is a real confounder in this literature and is why 'PRP' as a single word is close to meaningless. Xu B, et al. — [Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/41629990/). *Journal of orthopaedic surgery and research*, 2026. DOI: 10.1186/s13018-026-06689-4. 5. A systematic review and meta-analysis of adverse events associated with intra-articular PRP injections for knee OA, compared against other injectates. Included so the safety statement on these pages rests on a pooled adverse-event analysis rather than on the absence of reported harm in individual small trials. Nakagawa HF, et al. — [Assessment of adverse events and safety associated with intra-articular platelet-rich plasma injections compared to other injectates for knee osteoarthritis: A systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/42101047/). *PM & R : the journal of injury, function, and rehabilitation*, 2026. DOI: 10.1002/pmrj.70141. 6. OA-11, a 56-week phase 3 double-blind placebo-controlled trial, randomized 513 knee OA patients (KL 2-3) to a single intra-articular injection of the Wnt-pathway modulator lorecivivint or vehicle placebo. Lorecivivint MISSED its primary endpoint: 12-week pain NRS change was -2.24 with drug versus -2.49 with placebo (p=0.185), no other endpoint showed a discernible treatment effect, and neither group lost meaningful medial joint space over 52 weeks. Even a purpose-built, well-funded disease-modifying candidate has not beaten a placebo injection. Yazici Y, et al. — [A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/39808286/). *Clinical and experimental rheumatology*, 2025. DOI: 10.55563/clinexprheumatol/hjt118. 7. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative. Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 8. A meta-analysis of 9 Level-1 trials (671 patients) of adipose stromal vascular fraction and adipose-derived MSC injections for knee OA found SVF superior to saline or hyaluronic acid on pain and function at 3, 6 and 12 months - but INFERIOR to corticosteroid at 3 months, no different at 6, and only comparable or slightly superior at 12. Adipose-derived MSCs beat saline and conservative care but showed no significant difference versus HA. No serious adverse events were attributed to the injections themselves, though complications associated with the LIPOSUCTION step were observed. Han JH, et al. — [Intra-articular Stromal Vascular Fraction and Mesenchymal Stem Cell Injections Show Variable Efficacy and Higher Potential Complications Compared to Corticosteroid and Hyaluronic Acid in Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials.](https://pubmed.ncbi.nlm.nih.gov/39914607/). *Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association*, 2025. DOI: 10.1016/j.arthro.2025.01.050. 9. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products. US Food and Drug Administration, Center for Biologics Evaluation and Research — [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). *FDA*, 2020. ## Want to ask the clinic about your shoulder? QC Kinetix offers a Peoria visit to discuss PRP, or platelet-rich plasma from a platelet-heavy portion of spun blood. Other regenerative options may use blood or body tissue. Take your scan report, note the painful motions and ask about visits, cost and time away from normal activity. Call (602) 837-PAIN to check availability. Talk to the clinic team: --- Clear facts for a sore shoulder. Plain answers about shoulder soreness, home care and shoulder regeneration Peoria treatments made from blood or body tissue. Plain Peoria answers about shoulder soreness, home care and local help. This site is operated by the owners of the QC Kinetix Phoenix-area clinics, including the Peoria location, and the clinic group benefits when a reader books a consultation. © 2026 Peoria Shoulder Signal. General health education only; it is not a diagnosis or personal medical advice.